Member Info for draft

Iqai went from 1p.to 10p. The unloved shares fly up eventually. Hopefully same.for feedback

Its the shares no one is interested in that eventually have the huge moves.

come on guys, Coronavirus. China is out of action.

anyway whys is exry missing from the investors list?

The @FBKmed team is here at #IHUK @IntHealthAI - great to see @tara_donnelly1 discussing the NHSX Missions - We are passionate that #Bleepa has the potential to reduce the burden on frontline teams https://t.co/VzN1vd0OPn

Might as well. Particularly when MF told me theres no bad news and this will be a strong year for PAL

Fingers crossed for a takeover

Any other company would have said they are a takeover candidate and sp would have rocketed. Doing it this way tangent are keeping the sp under control.

To see what's under the hood in the numbers.

Is let's say Oldham et c agree to take on bleepa permanently ,how is feedback going to support the IT if there are glitches and it problems.

Theres no bad news cuz I phoned them. Just gonna have to wait for the numbers.

There must be old placees still holding stock. A few fed up traders from last year getting out also. I don't think Tom and Rory have done anything wrong to date. They inherited a pile from the previous bod.

Horsford. The big concern right now is the sp drop. Really Tom needs to get bleepa roll out news out asap.

That was a poor history with the old management and old board. This is a new board and they've already got a few new buns in the oven with the recent US deals. The large seller was probably just an aim trader getting out.

Coronavirus took the shine off every other stock unfortunately. pip bagged and was unloved. This will bounce back big.

NewsAppointment of Non-Executive Director
Pin to quick picksFeedback Regulatory News (FDBK)
FDBK Share Price
FDBK Share
Price
FDBK Share News
FDBK Share
News
1
FDBK Share Chat
FDBK Share
Chat
1
FDBK Share Trades
FDBK Share
Trades
14
FDBK Live RNS
FDBK
Live RNS
FDBK Information Buy FDBK SharesBuy FDBK SharesAdd FDBK to WatchlistAdd FDBK to WatchlistAdd FDBK to AlertAdd FDBK to AlertAdd FDBK to myTerminalAdd FDBK to myTerminal
Share Price Information for Feedback (FDBK)
London Stock Exchange
Share Price:
0.925
Bid:
0.90
Ask:
0.95
Change:
-0.025 (-2.63%)
Spread: 0.05 (5.56%)Open: 0.95High: 0.95Low: 0.925Yest. Close: 0.95
FDBK Live PriceLast checked at 16:24:36
Appointment of Non-Executive Director
Mon, 3rd Feb 2020 12:21

>
RNS Number : 7738B
Feedback PLC
03 February 2020

Feedback plc



Adam Denning, Former Assistant Technical Advisor to Bill Gates, Appointed as Non-Executive Director



London, 3 February 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company") is pleased to announce the appointment of Adam Denning as non-executive director of the Company with immediate effect. As former Assistant Technical Adviser to Bill Gates, he brings extensive software delivery skills to Feedback as roll-out of its secure, encrypted medical communication app for clinicians, Bleepa™ continues to gain momentum.



Adam currently serves as a non-executive director of Droplet Computing, an app containerisation startup, and as managing director of Logical Operators Limited, his own consultancy firm. Previously, he spent 25 years at Microsoft Corporation in various roles. From 2011-2017, he was a Partner Group Program Manager. In this role, he reported directly to the Corporate VP of the Windows platform, leading an international team of over 100 people and executing updates to Windows to deliver new customers. Before then, from 1999-2001, he served as an Assistant Technical Advisor to the Executive Office, presenting "demo days", where he would demonstrate internal and external technology to Bill Gates and attending all of his product reviews.



Rory Shaw, Chairman of Feedback, commented: "Adam has exceptional experience within the technology industry, especially in relation to project management and delivery, from his time at Microsoft. He brings valuable strategic input at an important time for us as we anticipate the commercial roll-out of Bleepa™. We are very pleased to have him join the Board."



Adam Denning added: "Feedback's technology has real potential to solve many of the issues faced by doctors and healthcare professionals on a daily basis around the world. The commercialisation of the Company's flagship product, Bleepa™ is especially exciting and could make a significant difference to how doctors and nurses can treat their patients."



In accordance with Rule 17 and Schedule Two paragraph (g) of the A

Impressive hire Bill Gates bloke. Share price should have gone flying up on that

Struggling to get over 1p

Will rerate up

some people have made 300% here from 12p

This will move back up.